Evaluation of transabdominal and transperineal ultrasound-derived prostate specific antigen (PSA) density and clinical utility compared to MRI prostate volumes: A feasibility study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
03
2022
accepted:
19
08
2022
entrez:
9
9
2022
pubmed:
10
9
2022
medline:
14
9
2022
Statut:
epublish
Résumé
To investigate the accuracy of surface-based ultrasound-derived PSA-density (US-PSAD) versus gold-standard MRI-PSAD as a risk-stratification tool. Single-centre prospective study of patients undergoing MRI for suspected prostate cancer (PCa). Four combinations of US-volumes were calculated using transperineal (TP) and transabdominal (TA) views, with triplanar measurements to calculate volume and US-PSAD. Intra-class correlation coefficient (ICC) was used to compare US and MRI volumes. Categorical comparison of MRI-PSAD and US-PSAD was performed at PSAD cut-offs <0.15, 0.15-0.20, and >0.20 ng/mL2 to assess agreement with MRI-PSAD risk-stratification decisions. 64 men were investigated, mean age 69 years and PSA 7.0 ng/mL. 36/64 had biopsy-confirmed prostate cancer (18 Gleason 3+3, 18 Gleason ≥3+4). Mean MRI-derived gland volume was 60 mL, compared to 56 mL for TA-US, and 65 mL TP-US. ICC demonstrated good agreement for all US volumes with MRI, with highest agreement for transabdominal US, followed by combined TA/TP volumes. Risk-stratification decisions to biopsy showed concordant agreement between triplanar MRI-PSAD and ultrasound-PSAD in 86-91% and 92-95% at PSAD thresholds of >0.15 ng/mL2 and >0.12 ng/mL2, respectively. Decision to biopsy at threshold >0.12 ng/mL2, demonstrated sensitivity ranges of 81-100%, specificity 85-100%, PPV 86-100% and NPV 83-100%. Transabdominal US provided optimal sensitivity of 100% for this clinical decision, with specificity 85%, and transperineal US provided optimal specificity of 100%, with sensitivity 87%. Transperineal-US and combined TA-TP US-derived PSA density values compare well with standard MRI-derived values and could be used to provide accurate PSAD at presentation and inform the need for further investigations.
Identifiants
pubmed: 36084119
doi: 10.1371/journal.pone.0274014
pii: PONE-D-22-06966
pmc: PMC9462719
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0274014Subventions
Organisme : Department of Health
ID : BRC-1215-20014
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C197/A16465
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Thorac Oncol. 2011 Jan;6(1):6-7
pubmed: 21178713
Eur Radiol. 2021 Jul;31(7):4908-4917
pubmed: 33398421
Br J Cancer. 2012 Sep 25;107(7):1195-202
pubmed: 22892390
Urology. 2020 Jul;141:125-129
pubmed: 32333985
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663
pubmed: 31022301
World J Urol. 2020 Mar;38(3):517-529
pubmed: 30868240
Eur Urol. 2019 Sep;76(3):340-351
pubmed: 30898406
Urol Int. 2007;78(4):323-7
pubmed: 17495490
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Br J Radiol. 2022 May 01;95(1133):20211372
pubmed: 35179971
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
BJU Int. 2018 Jul;122(1):13-25
pubmed: 29699001
J Urol. 2020 Apr;203(4):706-712
pubmed: 31642740
Eur Urol. 2019 Apr;75(4):570-578
pubmed: 30477981
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Br J Radiol. 2020 Apr;93(1108):20190929
pubmed: 31971823
BJU Int. 2021 Mar;127(3):304-306
pubmed: 33113258
Eur J Radiol. 2019 Nov;120:108660
pubmed: 31546123
Indian J Surg Oncol. 2012 Jun;3(2):120-9
pubmed: 23730101
J Urol. 2004 Oct;172(4 Pt 1):1297-301
pubmed: 15371827
Urol J. 2009 Summer;6(3):208-13
pubmed: 19711277
J Urol. 2017 Sep;198(3):575-582
pubmed: 28373135
BJU Int. 2020 Jan;125(1):49-55
pubmed: 31599113
Acad Radiol. 2021 Nov;28(11):1548-1556
pubmed: 32814644
Urology. 1998 Apr;51(4A Suppl):19-22
pubmed: 9586592
Clin Radiol. 2019 Nov;74(11):894.e1-894.e9
pubmed: 31288924
Eur Urol Oncol. 2019 May;2(3):311-319
pubmed: 31200846
Can Urol Assoc J. 2015 Nov-Dec;9(11-12):E853-8
pubmed: 26788234
Prostate Cancer. 2019 Mar 03;2019:6932572
pubmed: 30941221
AJR Am J Roentgenol. 2013 Nov;201(5):W720-9
pubmed: 24147502
Clin Radiol. 2019 Nov;74(11):841-852
pubmed: 31239107
Can Urol Assoc J. 2016 Aug;10(7-8):264-268
pubmed: 27878049
Sci Rep. 2016 Oct 17;6:35364
pubmed: 27748407
Eur Radiol. 2020 Oct;30(10):5404-5416
pubmed: 32424596
BJU Int. 2017 May;119(5):724-730
pubmed: 27488931
J Urol. 2000 Mar;163(3):806-12
pubmed: 10687982